Código QR (código de barras bidimensional)

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains most...

תיאור מלא

שמור ב:
Principais autores: Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2022-09-01
סדרה:Frontiers in Oncology
נושאים:
pancreatic cancer
PDAC
talazoparib
PARP inhibitors
PARPi
PALB2
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fonc.2022.953908/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים